UCB’s Bimzelx (Bimekizumab-bkzx) Secures the US FDA’s Approval for Treating Moderate to Severe Hidradenitis Suppurativa (HS)
Shots:
- The US FDA has granted approval to Bimzelx (IL-17F & IL-17A inhibitor) for treating adults with moderate to severe hidradenitis suppurativa (HS), based on P-III (BE HEARD I and BE HEARD II) studies
- BE HEARD I and BE HEARD II assessed the safety & efficacy of Bimzelx vs PBO for treating moderate to severe hidradenitis suppurativa (HS) in 1,014 patients, combined
- Study depicted >50% improvement in HS signs and symptoms as assessed by HiSCR50 (1EP) & meaningful improvements in HiSCR75 (2EP) at wk.16, with responses maintained through wk.48; safety profile was consistent. Results were published in The Lancet
Ref :UCB | Image:UCB
Related News:- UCB’s Bimzelx Receives CHMP’s Positive Opinion to Treat Moderate to Severe Hidradenitis Suppurativa
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
